(NASDAQ: VTYX) Ventyx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.66%.
Ventyx Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VTYX's revenue for 2026 to be $6,526,193,744, with the lowest VTYX revenue forecast at $6,526,193,744, and the highest VTYX revenue forecast at $6,526,193,744. On average, 2 Wall Street analysts forecast VTYX's revenue for 2027 to be $16,881,571,713, with the lowest VTYX revenue forecast at $185,019,123, and the highest VTYX revenue forecast at $33,578,124,304.
In 2028, VTYX is forecast to generate $29,366,092,817 in revenue, with the lowest revenue forecast at $583,521,848 and the highest revenue forecast at $58,148,663,785.